Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma

References

• Sennhauser FH, Braun-Fahrlander C, Wildhaber JH. The burden of asthma in children: a European perspective. Paediatr Respir Rev 2005;6:2-7
   PubMedGoogle Scholar
• Lai C, Beasley R, Crane J, et al. Global variation in the prevalence and severity of asthma symptoms: Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2009;64:476-83
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AM, Gaston BM, Erzurum SC, et al. Features of severe asthma in school-age children: atopy and increased exhaled nitric oxide. J Allergy Clin Immunol 2006;118:1218-25
   PubMed Web of Science ®Google Scholar
• Rabe KF, Vermeire PA, Soriano JB, et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000;16:802-7
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. Issued January 1995 (NIH Publication No. 02-3659); updated 2002, 2003, 2004, 2005, 2006, 2007, 2008. Available at: www.ginasthma.org [Last accessed 26 February 2010]
   Google Scholar
• Bai TR, Vonk JM, Postma DS, et al. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007;30:452-6
   PubMed Web of Science ®Google Scholar
• Marion RJ, Creer TL, Reynolds RV. Direct and indirect costs associated with the management of childhood asthma. Ann Allergy 1985;54:31-4
   PubMedGoogle Scholar
• Diette GB, Markson L, Skinner EA, et al. Nocturnal asthma in children affects school attendance, school performance, and parents’ work attendance. Arch Pediatr Adolesc Med 2000;154:923-8
   PubMed Web of Science ®Google Scholar
• Silverstein MD, Mair JE, Katusic SK, et al. School attendance and school performance: a population-based study of children with asthma. J Pediatr 2001;139:278-83
   PubMed Web of Science ®Google Scholar
• Kelly HW, Van Natta ML, Covar RA, et al. Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the childhood Asthma Management Program (CAMP) study. Pediatrics 2008;122:e53-61
   PubMed Web of Science ®Google Scholar
• National Heart, Lung and Blood Institute/National Asthma Education and Prevention Program (NHLBI/NAEPP 2007). Expert Panel Report 3: guidelines for the diagnosis and management of asthma, 2007. NIH Publication No. 07-4051. Available at: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm [Last accessed 22 December 2008]
   Google Scholar
• Bacharier LB, Boner A, Carlsen KH, et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy 2008;63:5-34
   PubMed Web of Science ®Google Scholar
• Bateman E, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836-44
   PubMed Web of Science ®Google Scholar
• Niven R, Chung KF, Panahloo Z, et al. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med 2008;102:1371-8
   PubMed Web of Science ®Google Scholar
• Bush A, Hedlin G, Carlsen KH, et al. Severe childhood asthma: a common international approach?. Lancet 2008;372:1019-21
   PubMed Web of Science ®Google Scholar
• Chipps BE, Szefler SJ, Simons FE, et al. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2007;119:1156-63
   PubMed Web of Science ®Google Scholar
• Randell T, Donaghue KC, Ambler GR, et al. Safety of the newer inhaled corticosteroids in childhood asthma. Paediatr Drugs 2003;5:481-504
   PubMedGoogle Scholar
• Todd GR, Acerini CL, Ross-Russell R, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002;87:457-61
   PubMed Web of Science ®Google Scholar
• Main C, Shepherd J, Anderson R, et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years. Health Technol Assess 2008;12:1-174,iii-iv
   PubMed Web of Science ®Google Scholar
• Bisgaard H. Effect of long-acting beta2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol 2003;36:391-8
   PubMed Web of Science ®Google Scholar
• Lange P, Parner J, Vestbo J, et al. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998;339:1194-200
   PubMed Web of Science ®Google Scholar
• Paull K, Covar R, Jain N, et al. Do NHLBI lung function criteria apply to children? A cross-sectional evaluation of childhood asthma at National Jewish Medical and Research Center, 1999–2002. Pediatr Pulmonol 2005;39:311-17
   PubMed Web of Science ®Google Scholar
• Spahn JD, Cherniack R, Paull K, et al. Is forced expiratory volume in one second the best measure of severity in childhood asthma?. Am J Respir Crit Care Med 2004;169:784-6
   PubMed Web of Science ®Google Scholar
• Bacharier LB, Strunk RC, Mauger D, et al. Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. Am J Respir Crit Care Med 2004;170:426-32
   PubMed Web of Science ®Google Scholar
• Bacharier L, Mauger D, Lemanske RJ, et al. Classifying asthma severity in children: is measuring lung function helpful?. J Allergy Clin Immunol 2002;109:S266
   Web of Science ®Google Scholar
• Arbes SJ Jr, Gergen PJ, Vaughn B, et al. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2007;120:1139-45
   PubMed Web of Science ®Google Scholar
• Borish L, Chipps B, Deniz Y, et al. Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2005;95:247-53
   PubMed Web of Science ®Google Scholar
• Genentech Inc: Omalizumab (Xolair®) full prescribing information (US), July 2007. Available at: www.gene.com/gene/products/information/immunological/xolair/insert.jsp [Last accessed 25 September 2009]
   Google Scholar
• European Medicines Agency (EMEA): Omalizumab (Xolair®) full prescribing information (EU), 2009. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Xolair/emea-combined-h606en.pdf [Last accessed 25 September 2009]
   Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90
   PubMed Web of Science ®Google Scholar
• Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-61 (erratum in Eur Respir J 2001;18:739-40)
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hébert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632-8
   PubMed Web of Science ®Google Scholar
• Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59:701-8
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis (SOLAR). Allergy 2004;59:709-17
   PubMed Web of Science ®Google Scholar
• Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302-8
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16
   PubMed Web of Science ®Google Scholar
• Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 2009;39:788-97
   PubMed Web of Science ®Google Scholar
• Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108:E36
   PubMed Web of Science ®Google Scholar
• Lanier R, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with uncontrolled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009;124:1210-16
   PubMed Web of Science ®Google Scholar
• NHLBI. The NAEPP Expert Panel Report: guidelines for the diagnosis and management of asthma-update on selected topics. NIH Publication No 02-5075, 2002
   Google Scholar
• van Elteren PH. On the combination of independent two-sample tests of Wilcoxon; Bull Int Stat Inst 1960;37:351-61
   Google Scholar
• MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438-45
   PubMed Web of Science ®Google Scholar